Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

Modern Retina - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

The company offers year-round educational services on the conditions, using this month in particular to guide patients to ...

The trial will feature the company’s product candidate, AXV101, focused on combating childhood blindness due to retinitis pigmentosa (RP) caused by Bardet-Biedl Syndrome 1 (BBS1). In December 2024, a ...

The objective of this trial was to evaluate safety and tolerability and identify dose level for further evaluation.

PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal ...

EYLEA’s unique MoA: What is the rationale for the higher molar dose?

A case report demonstrates independent effect of GLP-1 receptor agonist.

EYLEA’s unique MoA: What is the rationale for the higher molar dose?